title: Anticocaine catalytic antibodies.
abstract: Cocaine mediates its reinforcing and toxic actions through a "loss of function" effect at multiple receptors. The difficulties inherent in blocking a pleiotropic blocker pose a great obstacle for the classical receptor-antagonist approach and have contributed to the failure (to date) to devise specific treatments for cocaine overdose and addiction. As an alternative, we have embarked on an investigation of catalytic antibodies, a programmable class of artificial enzyme, as "peripheral blockers" -- agents designed to bind and degrade cocaine in the circulation before it partitions into the central nervous system to exert reinforcing or toxic effects. We synthesized transition-state analogs of cocaine's hydrolysis at its benzoyl ester, immunized mice, prepared hybridomas and developed the first anticocaine catalytic antibodies with the capacity to degrade cocaine to nonreinforcing, nontoxic products. We subsequently identified several families of anticocaine catalytic antibodies and found that the most potent antibody possessed sufficient activity to block cocaine-induced reinforcement, organ dysfunction and sudden death in rodent models of addiction, toxicity and overdose, respectively. With the potential to promote cessation of use, prolong abstinence and provide a treatment for acute overdose, the artificial enzyme approach comprehensively responds to the problem of cocaine.
authors.affiliation: Division of Clinical Pharmacology and Experimental Therapeutics, Department of Medicine, Columbia University, Box 84, 630 W 168th Street, New York, NY 10032, USA.
authors.forename: Shi Xian
authors.initials: SX
authors.lastname: Deng
authors.forename: Paloma
authors.initials: P
authors.lastname: de Prada
authors.forename: Donald W
authors.initials: DW
authors.lastname: Landry
mesh_terms: D000818:Animals; D017151:Antibodies, Catalytic / Q000378:metabolism* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000378:metabolism* / Q000627:therapeutic use; D003042:Cocaine / Q000276:immunology / Q000378:metabolism*; D019970:Cocaine-Related Disorders / Q000628:therapy; D022801:Complementarity Determining Regions; D006801:Humans
chemical_list: D017151:Antibodies, Catalytic; D000911:Antibodies, Monoclonal; D022801:Complementarity Determining Regions; D003042:Cocaine